This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Barnett, S. D. Articles by Davidson, J. R. T. Search for Related Content PubMed PubMed Citation Articles by Barnett, S. D. Articles by Davidson, J. R. T. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Phobias Social Bookmarking                         What's this?

Efficacy of olanzapine in social anxiety disorder: a pilot study

Michelle L. Kramer

Department of Psychiatry and Behavioural Sciences, Duke University Medical Center, DUMC, Durham, NC

Charles D. Casat

Behavioural Health Center, Charlotte, USA

Kathryn M. Connor

Jonathan R. T. Davidson

Department of Psychiatry and Behavioural Sciences, Duke University Medical Center, DUMC, Durham, NC

Based on evidence suggesting anxiolytic properties of the atypical antipsychotic olanzapine, this study was conducted to evaluate whether olanzapine may be efficacious in treating social anxiety disorder (SAD). This study was an 8-week, double-blind, placebo-controlled evaluation of olanzapine as monotherapy in which 12 patients with the DSM-IV diagnosis of SAD were randomized to either olanzapine (n= 7) or placebo (n= 5). An initial dose of 5 mg/day was titrated to a maximum of 20 mg/day. Baseline to endpoint scores from the Brief Social Phobia Scale (BSPS), Social Phobia Inventory (SPIN), Liebowitz Social Anxiety Scale and Sheehan Disability Scale, as well as Clinical Global Impression-Improvement ratings, were compared for olanzapine versus placebo. Seven subjects completed all 8 weeks of the study, four in the olanzapine group and three in the placebo group. In the intent-to-treat analysis, olanzapine yielded greater improvement than placebo on the primary measures: BSPS (p= 0.02) and SPIN (p= 0.01). Both treatments were well tolerated, although the olanzapine group had more drowsiness and dry mouth. Olanzapine and placebo were both associated with negligible weight gain. Olanzapine was superior to placebo on the primary outcome measures in this preliminary study of SAD. Additional studies of olanzapine as a treatment for SAD are warranted.

Key Words: Brief Social Phobia Scale • olanzapine • social anxiety disorder • Social Phobia Inventor

Journal of Psychopharmacology, Vol. 16, No. 4, 365-368 (2002)
DOI: 10.1177/026988110201600412


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. Delong and M. H. Pollack Update on the Assessment, Diagnosis, and Treatment of Individuals with Social Anxiety Disorder Focus, October 1, 2008; 6(4): 431 - 437. [Abstract] [Full Text] [PDF]

				M. H. Pollack, M. W. Otto, P. P. Roy-Byrne, J. D. Coplan, B. O. Rothbaum, N. M. Simon, and J. M. Gorman Novel Treatment Approaches for Refractory Anxiety Disorders Focus, October 1, 2008; 6(4): 486 - 495. [Abstract] [Full Text] [PDF]

				N. J. van der Wee, J. F. van Veen, H. Stevens, I. M. van Vliet, P. P. van Rijk, and H. G. Westenberg Increased Serotonin and Dopamine Transporter Binding in Psychotropic Medication-Naive Patients with Generalized Social Anxiety Disorder Shown by 123I-{beta}-(4-Iodophenyl)-Tropane SPECT J. Nucl. Med., May 1, 2008; 49(5): 757 - 763. [Abstract] [Full Text] [PDF]